ERS Respiratory Channel

CDN Connection Issue

It appears that your current network does not allow connection to the CDN (Content Delivery Network) required for this service to function properly.

To resolve this issue, please try the following actions :

• Contact your network administrator : Inform them of this restriction so they can adjust the network settings accordingly.

• Use another network : Try connecting from a different network, such as another Wi-Fi network or a mobile connection.

We apologize for the inconvenience and thank you for your understanding.

Abstract

Background

In the phase 3 DESTINATION (NCT03706079) study, long-term tezepelumab treatment resulted in reduced exacerbations, and improvements in lung function and symptom control, and reduced inflammatory biomarkers in patients with severe, uncontrolled asthma.

Objective
To explore the effects of tezepelumab cessation after 2 years of treatment (210 mg every 4 weeks).

Methods
DESTINATION was a multicentre, randomized, placebo-controlled, double-blind, extension study of patients (12?80 years old) who completed NAVIGATOR (NCT03347279) or SOURCE (NCT03406078). After tezepelumab cessation at week 104, patients who initially enrolled in NAVIGATOR could enter a 36-week off-treatment extended follow-up. Change over time in Asthma Control Questionnaire (ACQ)-6 score, blood eosinophils count (BEC), fractional exhaled nitric oxide (FeNO) levels and pre-bronchodilator (BD) FEV1 was assessed.

Results

Overall, 569 patients entered the extended follow-up. From week 110, ACQ-6 score increased, and BEC and FeNO levels gradually increased in parallel with pre-BD FEV1 reductions. All measures continued to worsen over the extended follow-up, but did not return to baseline 36 weeks post treatment cessation (Figure).

Conclusion

Biomarker suppression and improved clinical outcomes in patients gradually waned after cessation of tezepelumab, although, on average, none returned to baseline during the extended follow-up.

Abstract

#{title}